SlideShare une entreprise Scribd logo
1  sur  40
Disorders of Purine Metabolism

  Lecturer:
     Dr. G. K. Maiyoh
     Department of Medical
Biochemistry, School of Medicine,
               MU




March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013   1
Overview
•   Introduction
•   Purine (types)
•   Purine functions
•   Sources of purines
•   Metabolic disorders
•   Nucleotide degradation
•   Uric acid and hyperuricemia
•   In-born errors of Uric acid metabolism
•   Disorders due to purine catabolism
•   Disorders due to salvage pathway

March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013   2
WHAT ARE PURINES?
• Purines are heterocyclic
  compound consisting of
  a pyrimidine ring fused
  to an imidazole Ring




 March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013   3
Purines
• Other minor purine base include:
1. Xanthine
2. Hypoxanthine
3. Uric acid
• The above occur in free state in the cells
4 N6 –Methyladenine
5 N6 N6 Dimethyladenine
6 N7-Methylguanine
• Occur in mamalian RNA

March 21, 2013    GKM/MUSOM/NSP 210:PATH.2012.2013   4
PURINES
7 1,3-Dimethylxanthine(theophylline) found in
   TEA
8 3,7-Dimethylxanthine(theobromine)found in
   COCOA
9 1,3,7-Trimethylxanthine(caffiene ) found in
   coffee
This are pharmacologically important


March 21, 2013   GKM/MUSOM/NSP 210:PATH.2012.2013   5
Functions
Key functions include;
Provision of Energy e.g. ATP, GTP
Building blocks for DNA and RNA (along side
  pyrimidines)
Basic conenzymes i.e. NAD and NADH
Play role in signal transduction e.g GTP, cAMP,
  cGMP

March 21, 2013   GKM/MUSOM/NSP 210:PATH.2012.2013   6
Sources of purine
ENDOGENOUS
•       They may be synthesized DE NOVO
  from small molecules

EXOGENOUS
•        They may be derived from the
  breakdown of ingested nucleic acid,mostly
  from cell-rich meat
• Plant diets generally poor in purines

March 21, 2013     GKM/MUSOM/NSP 210:PATH.2012.2013   7
Metabolic disorders of purines
• They cover a broad spectrum of illnesses with
  various presentations. Examples of
  presentations include;
             •   Hyperuricemia
             •   Acute renal failure
             •   Gout
             •   Unexplained neurologic defects (seizures, muscle
                 weakness e.tc)
             •   Developmental disorders
             •   Compulsive self injury and aggression
             •   Immune deficiency
             •   Deafness
March 21, 2013               GKM/MUSOM/NSP 210:PATH.2012.2013       8
Major Categories of Disorders

    Two major types of disorders occur;
          i.  Those that arise from a Blockage in purine
              nucleotide degradation pathway
          ii. Arising from increased activity of nucleotide
              degradation pathway




March 21, 2013          GKM/MUSOM/NSP 210:PATH.2012.2013      9
Nucleotide degradation
•   Nucleic acids can survive the acid of the stomach
•   They are degraded into nucleotides by pancreatic
    nucleases and intestinal phosphodiesterases in the
    duodenum.
•   Components cannot pass through cell membranes, so
    they are further hydrolyzed to nucleosides.
•   Nucleosides may be directly absorbed by the intestine or
    undergo further degradation to free bases and ribose or
    ribose-1-phosphate by nucleosidases and nucloside
    phosphorylase.
                           nucleosidase


    Nucleoside + H2O    Nucleoside           base + ribose
                        phosphorylase



    Nucleoside + Pi                       base + ribose-1-P
Catabolism of purines




                   ADA




  Major pathways of purine
   catabolism in animals.



  March 21, 2013         GKM/MUSOM/NSP 210:PATH.2012.2013   11
Catabolism of purines
•Purine nucleotide degradation refers to a regulated series of reactions
by which purine ribonucleotides and deoxyribonucleotides are degraded
to uric acid in humans.
•As indicated earlier, two major types of disorders occur in this pathway;
    • A block of degradation occurs with syndromes involving;-
         • immune deficiency.
         •myopathy or
         •renal calculi.
    •Increased degradation of nucleotides occurs with syndromes
    characterized by;-
         • hyperuricemia and gout,
         •renal calculi,
         •anemia or acute hypoxia.

 March 21, 2013           GKM/MUSOM/NSP 210:PATH.2012.2013              12
Uric Acid (2,6,8-trioxypurine)
 • This is the end product of purine metabolism in
   humans
 • Accumulation of uric acid in blood is reffered to as
   hyperuricemia
 • Uric acid is highly insoluble therefore a very slight
   alteration in the production or solubility will increase
   levels in blood.
 • Due to poor solubility, levels in blood are usually
   near the maximal tolerable limits


March 21, 2013      GKM/MUSOM/NSP 210:PATH.2012.2013     13
Excretion of uric acid
• Uric acid is filtered through the glomeruli and most is
  reabsorbed in the proximal tubules.

• More than 80% of uric acid formed in the urine is
  derived from distal tubular secretion

• Urinary excretion is slightly lower in males than
  females,which may contribute to the higher incidence
  of hyperuricaemia in men

• Renal secretion may be enhanced by uricosonic
  drugs(e.g probenecid or sulfinpyrazone),which block
  tubular urate reabsorption
Excretion of uric acid
• 75% urate leaving the body is in urine
• The remaining 25% passes into the intestinal
  lumen,where it is broken down by intestinal
  bacteria(URICOLYCIS)
HYPERURICAEMIA
• This is increase in blood levels of uric acid that
  is greater than 0.42 mmol/l in men and more
  than 0.36mmol/l in women

• It can occur by two mechanisms:
•     1 Increased production(Over Production)
•     2 Decreased Excretion (under excretors)
Conditions that lead to Increased
         Uric acid Production
      – Malignancies
      – Reyes Syndrome
      – Downs Syndrome
      – Sickle cell anemia
      – Glycogen storage diseases types I,III, IV and V
      – Hereditary fructose intolerance
      – Gout
      – AcylCoA dehydroginase defficiency

March 21, 2013        GKM/MUSOM/NSP 210:PATH.2012.2013    17
Factors contributing to Hyperuraecimia

• Increased synthesis of purines(primary Gout)

• Secondary GOUT (Other disorder in which there is rapid
  tissue break down or rapid cellular turnover)

• Increase intake of purines

• Increase turnover of Nucleic Acids

• Increased rate of urate formation

• Reduced rate of Excretion
Factors contributing to Hyperuraecimia
• Sex(plasma uric acid is higher in male than
  females)
• Obesity (Obese people tends to high plasma
  level of urate)
• Diet (subject with high protein diet ,which is also
  rich in NUCLIEC acids and who do have high
  alcohol consumption have high levels of plasma
  urate
• Genetic factor(These are very important factor in
  high plasma urate levels)
Other causes may include:
• Eclampsia
• Lead toxicity
• Chronic alcohol ingestion

• NOTE Hypouricaemia is not an important
  chemical disorder in itself
Management of disorders
     Management of disorders of purine nucleotide
     degradation is dependent upon modifying the specific
     molecular pathology underlying each disease state.




March 21, 2013        GKM/MUSOM/NSP 210:PATH.2012.2013      21
Common treatment for gout: allopurinol




      Allopurinol is an analogue of hypoxanthine that strongly inhibits
      xanthine oxidase. Xanthine and hypoxanthine, which are soluble, are
      accumulated and excreted.


March 21, 2013             GKM/MUSOM/NSP 210:PATH.2012.2013                 22
In born errors of Uric Acid Metabolism
1. Phosphorybosylpyrophosphate synthase (PRS)
   superactivity
    There are two form;
       i. The severe form which appears in infancy
       ii. The mild form which presents in adolescence
          •          In both forms, kidney or bladder stone is often the first
                  symptom.
          •       Gout and impairment of kidney function may develop if the
                  condition is not adequately controlled with medication and
                  dietary restrictions.




 March 21, 2013                GKM/MUSOM/NSP 210:PATH.2012.2013                  23
2. Adenylosuccinase deficiency

      • Due to lack of the enzyme adenylosuccinate
        lyase

      • In general, affected individuals may have a
        mix of neurological symptoms, which usually
        includes abnormalities with cognition and
        movement, autistic features, epilepsy, muscle
        wasting, and feeding problems.



March 21, 2013      GKM/MUSOM/NSP 210:PATH.2012.2013   24
Disorders due to purine catabolism




March 21, 2013           GKM/MUSOM/NSP 210:PATH.2012.2013   25
Myoadenylate Deaminase Deficiency
• Also called muscle adenosine monophosphate
  deaminase deficiency
• This is a genetic disease that interferes with the
  muscle cell's processing of ATP, the key energy
  molecule of a cell.
• The lack of an enzyme that converts ATP to
  inosine and ammonia may present no symptoms
  or it may cause exercise-induced cramping.
• The disorder is diagnosed through the
  accumulation of ammonia or inosine
  monophosphate in muscle tissue
• Treatment typically consists of exercise
  modulation.
March 21, 2013     GKM/MUSOM/NSP 210:PATH.2012.2013    26
Xanthine Oxidase Deficiency
       (XANTHINURIA)
• This is a rare hereditary disorder in which
  there is a deficiency of liver xanthine oxidase
• The catabolism of purine stops with xanthine-
  hypoxanthine stones.
• The blood uric acid is very low and there is a
  high level of urinary excretion of xanthine
• There is reduced excretion of urinary uric acid
Xanthine Oxidase Deficiency
 (Xanthinuria)
•Xanthine oxidase deficiency, is an inherited
metabolic disorder in which there is deficiency of an
enzyme needed to process xanthine, a substance
found in caffeine and related substances.
•If left untreated, xanthinuria can lead to kidney stone
formation and subsequent urinary tract diseases.
•Additionally, this condition can lead to muscle
disorders, due to deposits of xanthine in muscle
tissue.
•Treatment of the condition involves avoiding foods
and drinks that contain xanthine derivatives, such as
coffee, tea and colas and maintaining a high fluid 28
March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013
Adenosine Deaminase Deficiency
   • This is a genetic disorder that impairs the immune
        system and is the basis of severe combined
        immunodeficiency, or SCID.
   • Children diagnosed with SCID are typically
        deficient in almost all immune protection from
        pathogens and are vulnerable to chronic infections
        caused by "opportunistic" organisms that ordinarily
        do not cause disease in healthy people with a
        normal immune response.
   • Symptoms of SCID include pneumonia and
        chronic diarrhea, with impeded growth compared
        to healthy children.
   • Additionally, neurological problems such as
        developmentalGKM/MUSOM/NSPmotor function disorders and
March 21, 2013          delay, 210:PATH.2012.2013           29
Disorders due to salvage pathway
     A salvage pathway is a pathway in which nucleotides (Purine and
     pyrimidine) are synthesized from intermediates in the degradative pathway
     for nucleotides.

There are two critical enzyme defficiencies;
I. Hypoxanthine guanige phosphorybosyltransferase (HPRT)
    defficiency
      –               May be total (Lesch-Nyhan syndrome ) or partal
             defficiency
             Partial HPRT-deficient patients present with symptoms similar to
             total but with a reduced intensity, and in the least severe forms
             symptoms may be unapparent.
I.        Adenine phosphorybosyltransferase (APRT) defficiency
      –       The disorder results in accumulation of the insoluble Purine 2,8-
              dihydroxyadenine.
     –        It can result in nephrolithiasis (kidney stones), acute renal failure
March 21, 2013and permanent kidney damage.
                                 GKM/MUSOM/NSP 210:PATH.2012.2013                     30
Lesch-Nyhan Syndrome
• Lesch-Nyhan syndrome is a metabolic disorder
    caused by a deficiency of an enzyme (HPRT)
    produced by mutations in a gene located on the X
    chromosome.
• The disease is marked by a buildup of uric acid in all
    body fluids that results in conditions known as
    hyperuricemia and hyperuricosuria.
• Symptoms often include severe gout, impaired
    muscular control, moderate mental retardation and
    kidney problems.
• These complications frequently emerge in the first
    year of life. Neurological symptoms can include
 March 21, 2013 grimacing, GKM/MUSOM/NSP 210:PATH.2012.2013
    facial                  involuntary writhing and repetitive31
Gout
• Characterised by the accumulation of
  monosodium urate crystal deposits which
  result in inflamation in joints and surrounding
  tissues.
• Presentation
    – Hyperuricemia
    – Uric acid nephrolithiasis
    – Acute inflamatory arthritis



 March 21, 2013      GKM/MUSOM/NSP 210:PATH.2012.2013   32
Gout
• Commonly monoarticular (Affecting the
  metatarsophalangeal joint of the big toe.
• However deposits of sodium urates may aslo
  occur in;
      – The elbows
      – Knees
      – Feet
      – Helix of the ear

March 21, 2013        GKM/MUSOM/NSP 210:PATH.2012.2013   33
Figure 28-29 The Gout, a cartoon by James Gilroy (1799).
Page 1097




              Gout is a disease characterized by elevated levels of uric acid in body fluids.
              Caused by deposition of nearly insoluble crystals of sodium urate or uric acid.

            March 21, 2013              GKM/MUSOM/NSP 210:PATH.2012.2013                    34
Types of Gout
• Primary Gout
     – Occurrence: Middle aged men (mostly)
     – Cause: Overproduction of Uric Acid
              Decreased renal excretion
              or both
     Biochemical Etiology: Not clearly known and is
       considered a polygenic disease



March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013   35
Types of Gout
• Secondary Gout
      – Occurrence: Children
      – Cause: other condition in which there is rapid
        tissue breakdown or cellular turnover
      – Such condition leads to either;
             • Increased production of Uric acid
             • Decreased clearance of Uric acid




March 21, 2013             GKM/MUSOM/NSP 210:PATH.2012.2013   36
Other conditions that could lead to
gout
• Any other condition that may lead to
  either;
      – Decreased uric acid clearance or
      – Increase in production

      These may include;                            Also;
      • Malignancy therapy                          •Excessive purine intake
                                                    •Alcohol intake
      • Dehydration                                 •Carbohydrate ingestion
      • Lactic acidosis
      • Ketoacidosis
      • Stavation
      • Diuretic therapy
      • Renal failure
March 21, 2013             GKM/MUSOM/NSP 210:PATH.2012.2013                    37
Hereditary disorders associated
with gout
• These include 3 key enzymes resulting in
  hyperuricemia
• These are;
      1. Severe HPRT defficiency (Lesch-Nyhan
         syndrome)
             •   Also Partial HPRT defficiency
      1. Superactivity of PP-ribose-p synthetase
      2. Glucose -6-phosphatase defficiency (glycogen
         storage disease type 1)
March 21, 2013              GKM/MUSOM/NSP 210:PATH.2012.2013   38
Hereditary disorders associated
with gout - cnt
• 1st two are caused by hyperuricemia due to
  purine nucleotide and uric acid
  overproduction
• The 3rd due to excess uric acid production and
  impaired uric acid secretion




March 21, 2013   GKM/MUSOM/NSP 210:PATH.2012.2013   39
Familial Juvenile Gout (Familial Juvenile
     Hyperuricemic Nephropathy (FJHN)
• Due to severe renal hypoexcretion of uric acid
• Presentation usually occurs at puberty to the
  3rd decade
     – Has also been reported in infancy
     Characteristics
     – Hyperuricemia
     – Gout
     – Familial renal disease
     – Low urate clearance relative to GFR
March 21, 2013       GKM/MUSOM/NSP 210:PATH.2012.2013   40

Contenu connexe

Tendances

De novo and salvage pathway of purines
De novo and salvage pathway of purinesDe novo and salvage pathway of purines
De novo and salvage pathway of purinesPRADIP HIRAPURE
 
PHENYLALANINE METABOLISM
PHENYLALANINE METABOLISMPHENYLALANINE METABOLISM
PHENYLALANINE METABOLISMYESANNA
 
Biosynthesis of Purine Ribonucleotide, Gout
Biosynthesis of Purine Ribonucleotide, GoutBiosynthesis of Purine Ribonucleotide, Gout
Biosynthesis of Purine Ribonucleotide, GoutAshok Katta
 
GLYCINE METABOLISM
GLYCINE METABOLISMGLYCINE METABOLISM
GLYCINE METABOLISMYESANNA
 
Metabolism of amino acids (general metabolism)
Metabolism of amino acids (general metabolism)Metabolism of amino acids (general metabolism)
Metabolism of amino acids (general metabolism)Ashok Katta
 
Sulphur containing amino acids metabolism
Sulphur containing  amino acids metabolism Sulphur containing  amino acids metabolism
Sulphur containing amino acids metabolism Dhiraj Trivedi
 
Fructose metabolism
Fructose metabolismFructose metabolism
Fructose metabolismrohini sane
 
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)Ashok Katta
 
Purine degradation
Purine degradationPurine degradation
Purine degradationsridevi244
 
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)Anup Shamsher Budhathoki
 
BRANCHED CHAIN AMINO ACID METABOLISM
BRANCHED CHAIN AMINO ACID METABOLISMBRANCHED CHAIN AMINO ACID METABOLISM
BRANCHED CHAIN AMINO ACID METABOLISMYESANNA
 
Urea cycle and disorder
Urea cycle and disorderUrea cycle and disorder
Urea cycle and disorderfarranajwa
 
Glycogen storage disease (gsd)
Glycogen                  storage                    disease (gsd)Glycogen                  storage                    disease (gsd)
Glycogen storage disease (gsd)promotemedical
 
GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES YESANNA
 
Gluconeogenesis- Steps, Regulation and clinical significance
Gluconeogenesis- Steps, Regulation and clinical significanceGluconeogenesis- Steps, Regulation and clinical significance
Gluconeogenesis- Steps, Regulation and clinical significanceNamrata Chhabra
 
PYRIMIDINE SYNTHESIS
PYRIMIDINE SYNTHESISPYRIMIDINE SYNTHESIS
PYRIMIDINE SYNTHESISYESANNA
 
Gluconeogenesis -
Gluconeogenesis - Gluconeogenesis -
Gluconeogenesis - Ashok Katta
 
PURINE DEGRADATION & GOUT
PURINE DEGRADATION & GOUTPURINE DEGRADATION & GOUT
PURINE DEGRADATION & GOUTYESANNA
 

Tendances (20)

De novo and salvage pathway of purines
De novo and salvage pathway of purinesDe novo and salvage pathway of purines
De novo and salvage pathway of purines
 
PHENYLALANINE METABOLISM
PHENYLALANINE METABOLISMPHENYLALANINE METABOLISM
PHENYLALANINE METABOLISM
 
Biosynthesis of Purine Ribonucleotide, Gout
Biosynthesis of Purine Ribonucleotide, GoutBiosynthesis of Purine Ribonucleotide, Gout
Biosynthesis of Purine Ribonucleotide, Gout
 
GLYCINE METABOLISM
GLYCINE METABOLISMGLYCINE METABOLISM
GLYCINE METABOLISM
 
Metabolism of amino acids (general metabolism)
Metabolism of amino acids (general metabolism)Metabolism of amino acids (general metabolism)
Metabolism of amino acids (general metabolism)
 
Purine metabolism
Purine metabolismPurine metabolism
Purine metabolism
 
Sulphur containing amino acids metabolism
Sulphur containing  amino acids metabolism Sulphur containing  amino acids metabolism
Sulphur containing amino acids metabolism
 
Fructose metabolism
Fructose metabolismFructose metabolism
Fructose metabolism
 
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)
Metabolism of Brached Chain Amino Acid (Valine, Isoleucine, Leucine)
 
Purine degradation
Purine degradationPurine degradation
Purine degradation
 
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)
Fatty acid oxidation ( Beta , Alpha omega and peroxisomal)
 
BRANCHED CHAIN AMINO ACID METABOLISM
BRANCHED CHAIN AMINO ACID METABOLISMBRANCHED CHAIN AMINO ACID METABOLISM
BRANCHED CHAIN AMINO ACID METABOLISM
 
Urea cycle and disorder
Urea cycle and disorderUrea cycle and disorder
Urea cycle and disorder
 
Glycogen storage disease (gsd)
Glycogen                  storage                    disease (gsd)Glycogen                  storage                    disease (gsd)
Glycogen storage disease (gsd)
 
GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
 
Gluconeogenesis- Steps, Regulation and clinical significance
Gluconeogenesis- Steps, Regulation and clinical significanceGluconeogenesis- Steps, Regulation and clinical significance
Gluconeogenesis- Steps, Regulation and clinical significance
 
Biosynthesis of purine & pyrimidine
Biosynthesis of purine & pyrimidine Biosynthesis of purine & pyrimidine
Biosynthesis of purine & pyrimidine
 
PYRIMIDINE SYNTHESIS
PYRIMIDINE SYNTHESISPYRIMIDINE SYNTHESIS
PYRIMIDINE SYNTHESIS
 
Gluconeogenesis -
Gluconeogenesis - Gluconeogenesis -
Gluconeogenesis -
 
PURINE DEGRADATION & GOUT
PURINE DEGRADATION & GOUTPURINE DEGRADATION & GOUT
PURINE DEGRADATION & GOUT
 

En vedette

Metabolisme purin
Metabolisme purinMetabolisme purin
Metabolisme purinNabil Hariz
 
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA Operator Warnet Vast Raha
 
Metabolisme purin dan pirimidin
Metabolisme purin dan pirimidinMetabolisme purin dan pirimidin
Metabolisme purin dan pirimidinRifki Imun
 
Metabolisme Purin Primidin
Metabolisme Purin PrimidinMetabolisme Purin Primidin
Metabolisme Purin PrimidinDedi Kun
 
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS santosh Kumbhar
 
Topic reciprocal regulation of purine and pyrimidine metabolism
Topic reciprocal regulation of purine and pyrimidine metabolismTopic reciprocal regulation of purine and pyrimidine metabolism
Topic reciprocal regulation of purine and pyrimidine metabolismjadabkishore
 
Purine catabolism
Purine catabolism Purine catabolism
Purine catabolism ranjani n
 
Publications-Dennis Huszar
Publications-Dennis HuszarPublications-Dennis Huszar
Publications-Dennis HuszarDennis Huszar
 
Molecular docking
Molecular dockingMolecular docking
Molecular dockingpalliyath91
 
Materi Tentang Metabolisme purin,pirimidin
Materi Tentang Metabolisme purin,pirimidinMateri Tentang Metabolisme purin,pirimidin
Materi Tentang Metabolisme purin,pirimidinyohanes meor
 
materi tentang Dna,rna,metabolisme purin,pirimidin
materi tentang Dna,rna,metabolisme purin,pirimidinmateri tentang Dna,rna,metabolisme purin,pirimidin
materi tentang Dna,rna,metabolisme purin,pirimidinyohanes meor
 
Gout presentation
Gout presentationGout presentation
Gout presentationKochi Chia
 

En vedette (20)

Metabolisme purin
Metabolisme purinMetabolisme purin
Metabolisme purin
 
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA
Word klmpok 1.metabolis purin dan pirimidin AKBID PARAMATA RAHA
 
Caffeine and You
Caffeine and YouCaffeine and You
Caffeine and You
 
Metabolisme purin dan pirimidin
Metabolisme purin dan pirimidinMetabolisme purin dan pirimidin
Metabolisme purin dan pirimidin
 
Metabolisme Purin Primidin
Metabolisme Purin PrimidinMetabolisme Purin Primidin
Metabolisme Purin Primidin
 
Molybdenum
MolybdenumMolybdenum
Molybdenum
 
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS
 
Topic reciprocal regulation of purine and pyrimidine metabolism
Topic reciprocal regulation of purine and pyrimidine metabolismTopic reciprocal regulation of purine and pyrimidine metabolism
Topic reciprocal regulation of purine and pyrimidine metabolism
 
Purine pyrimidine metabolism and disorder
Purine pyrimidine metabolism and disorderPurine pyrimidine metabolism and disorder
Purine pyrimidine metabolism and disorder
 
Purine catabolism
Purine catabolism Purine catabolism
Purine catabolism
 
Gout
GoutGout
Gout
 
Publications-Dennis Huszar
Publications-Dennis HuszarPublications-Dennis Huszar
Publications-Dennis Huszar
 
MOLECULAR DOCKING
MOLECULAR DOCKINGMOLECULAR DOCKING
MOLECULAR DOCKING
 
Molecular docking
Molecular dockingMolecular docking
Molecular docking
 
Materi Tentang Metabolisme purin,pirimidin
Materi Tentang Metabolisme purin,pirimidinMateri Tentang Metabolisme purin,pirimidin
Materi Tentang Metabolisme purin,pirimidin
 
materi tentang Dna,rna,metabolisme purin,pirimidin
materi tentang Dna,rna,metabolisme purin,pirimidinmateri tentang Dna,rna,metabolisme purin,pirimidin
materi tentang Dna,rna,metabolisme purin,pirimidin
 
Anti cancer drugs
Anti cancer drugsAnti cancer drugs
Anti cancer drugs
 
Chocolate Presentation
Chocolate PresentationChocolate Presentation
Chocolate Presentation
 
Chocolates presentation
Chocolates presentationChocolates presentation
Chocolates presentation
 
Gout presentation
Gout presentationGout presentation
Gout presentation
 

Similaire à Disorders of Purine Metabolism Lecture

Genetics, IEM.ppt
Genetics, IEM.pptGenetics, IEM.ppt
Genetics, IEM.pptLaxmiDahal7
 
Management of uremic complications
Management of uremic complicationsManagement of uremic complications
Management of uremic complicationsHarsh shaH
 
Pharmakokinetic Variations in Kidney diseases.
Pharmakokinetic Variations in Kidney diseases.Pharmakokinetic Variations in Kidney diseases.
Pharmakokinetic Variations in Kidney diseases.Maleha Sial
 
Purines metabolism.pptx
Purines metabolism.pptxPurines metabolism.pptx
Purines metabolism.pptxDRx Chaudhary
 
Metabolic 5 5-2013
Metabolic 5 5-2013Metabolic 5 5-2013
Metabolic 5 5-2013Azad Haleem
 
Inborn errors of metabolism
Inborn errors of metabolismInborn errors of metabolism
Inborn errors of metabolismMohammed Ellulu
 
Pathophysiology and clinical management of gouty arthritis
Pathophysiology and clinical management of gouty arthritisPathophysiology and clinical management of gouty arthritis
Pathophysiology and clinical management of gouty arthritisSoujanya Pharm.D
 
HYPERURICAEMIA + all related brand training material.pptx
HYPERURICAEMIA  + all related brand training material.pptxHYPERURICAEMIA  + all related brand training material.pptx
HYPERURICAEMIA + all related brand training material.pptxPabitra Thapa
 
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdf
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdfOJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdf
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdfEasyrexjunior
 
Genetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalGenetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalFarragBahbah
 
Genetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalGenetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalFarragBahbah
 
DEGRADATION OF PURINE WRITE UP.docx
DEGRADATION OF PURINE WRITE UP.docxDEGRADATION OF PURINE WRITE UP.docx
DEGRADATION OF PURINE WRITE UP.docxSNEHA AGRAWAL GUPTA
 
Chronic Kidney Disease in Pediatrics
Chronic Kidney Disease in PediatricsChronic Kidney Disease in Pediatrics
Chronic Kidney Disease in PediatricsDrhunny88
 
Diagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in ChildrenDiagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in ChildrenAzad Haleem
 
Principles of Hormonal regulations
Principles of Hormonal regulationsPrinciples of Hormonal regulations
Principles of Hormonal regulationsEneutron
 

Similaire à Disorders of Purine Metabolism Lecture (20)

Msp 304. gsd,gout,a cuduria and lesh.2014
Msp 304. gsd,gout,a cuduria and lesh.2014Msp 304. gsd,gout,a cuduria and lesh.2014
Msp 304. gsd,gout,a cuduria and lesh.2014
 
Genetics, IEM.ppt
Genetics, IEM.pptGenetics, IEM.ppt
Genetics, IEM.ppt
 
Nucleotide metabolism
Nucleotide metabolism Nucleotide metabolism
Nucleotide metabolism
 
Gouty arthritis
Gouty arthritisGouty arthritis
Gouty arthritis
 
Gouty arthritis - NOTES
Gouty arthritis - NOTESGouty arthritis - NOTES
Gouty arthritis - NOTES
 
Management of uremic complications
Management of uremic complicationsManagement of uremic complications
Management of uremic complications
 
Pharmakokinetic Variations in Kidney diseases.
Pharmakokinetic Variations in Kidney diseases.Pharmakokinetic Variations in Kidney diseases.
Pharmakokinetic Variations in Kidney diseases.
 
Purines metabolism.pptx
Purines metabolism.pptxPurines metabolism.pptx
Purines metabolism.pptx
 
Metabolic 5 5-2013
Metabolic 5 5-2013Metabolic 5 5-2013
Metabolic 5 5-2013
 
Inborn errors of metabolism
Inborn errors of metabolismInborn errors of metabolism
Inborn errors of metabolism
 
Pathophysiology and clinical management of gouty arthritis
Pathophysiology and clinical management of gouty arthritisPathophysiology and clinical management of gouty arthritis
Pathophysiology and clinical management of gouty arthritis
 
Inbornerrorsofmet
InbornerrorsofmetInbornerrorsofmet
Inbornerrorsofmet
 
HYPERURICAEMIA + all related brand training material.pptx
HYPERURICAEMIA  + all related brand training material.pptxHYPERURICAEMIA  + all related brand training material.pptx
HYPERURICAEMIA + all related brand training material.pptx
 
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdf
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdfOJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdf
OJEMEKELE-O-BCM-225-LECTURE-ON-INBORN-ERRORSOER8115417.pdf
 
Genetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalGenetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shal
 
Genetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shalGenetic based renal transport disorder dr rani shal
Genetic based renal transport disorder dr rani shal
 
DEGRADATION OF PURINE WRITE UP.docx
DEGRADATION OF PURINE WRITE UP.docxDEGRADATION OF PURINE WRITE UP.docx
DEGRADATION OF PURINE WRITE UP.docx
 
Chronic Kidney Disease in Pediatrics
Chronic Kidney Disease in PediatricsChronic Kidney Disease in Pediatrics
Chronic Kidney Disease in Pediatrics
 
Diagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in ChildrenDiagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in Children
 
Principles of Hormonal regulations
Principles of Hormonal regulationsPrinciples of Hormonal regulations
Principles of Hormonal regulations
 

Plus de Dr. Geoffrey K. K. Maiyoh

Msb 206. amino acid catab and fates of cs.2014
Msb 206. amino acid catab and fates of cs.2014Msb 206. amino acid catab and fates of cs.2014
Msb 206. amino acid catab and fates of cs.2014Dr. Geoffrey K. K. Maiyoh
 
Cellular respiration (glycolysis, TCA and ETC)
Cellular respiration (glycolysis, TCA and ETC)Cellular respiration (glycolysis, TCA and ETC)
Cellular respiration (glycolysis, TCA and ETC)Dr. Geoffrey K. K. Maiyoh
 
Chemistry of Carbohydrates and Nucleic acids - An introduction
Chemistry of Carbohydrates and Nucleic acids - An introductionChemistry of Carbohydrates and Nucleic acids - An introduction
Chemistry of Carbohydrates and Nucleic acids - An introductionDr. Geoffrey K. K. Maiyoh
 

Plus de Dr. Geoffrey K. K. Maiyoh (20)

Cancer in kenya
Cancer in kenyaCancer in kenya
Cancer in kenya
 
Celebrating Kenya
Celebrating KenyaCelebrating Kenya
Celebrating Kenya
 
Lecture 05.2014
Lecture 05.2014Lecture 05.2014
Lecture 05.2014
 
Lecture 04.2014
Lecture 04.2014Lecture 04.2014
Lecture 04.2014
 
Lecture 03.2014
Lecture 03.2014Lecture 03.2014
Lecture 03.2014
 
Classes of antimicrobial agents
Classes of antimicrobial agentsClasses of antimicrobial agents
Classes of antimicrobial agents
 
Lecture 01.2014
Lecture 01.2014Lecture 01.2014
Lecture 01.2014
 
Mineralocorticoids & glucocorticoids
Mineralocorticoids & glucocorticoidsMineralocorticoids & glucocorticoids
Mineralocorticoids & glucocorticoids
 
Molecular diagnostics
Molecular diagnosticsMolecular diagnostics
Molecular diagnostics
 
obesity diabetes and metabolic syndrome
obesity diabetes and metabolic syndromeobesity diabetes and metabolic syndrome
obesity diabetes and metabolic syndrome
 
Dsb 106. intergration of metabolism.2014
Dsb 106. intergration of metabolism.2014Dsb 106. intergration of metabolism.2014
Dsb 106. intergration of metabolism.2014
 
Bpt 114. purine and pyrimidine metabolism
Bpt 114. purine and pyrimidine metabolismBpt 114. purine and pyrimidine metabolism
Bpt 114. purine and pyrimidine metabolism
 
Msb 206. amino acid catab and fates of cs.2014
Msb 206. amino acid catab and fates of cs.2014Msb 206. amino acid catab and fates of cs.2014
Msb 206. amino acid catab and fates of cs.2014
 
Cellular respiration (glycolysis, TCA and ETC)
Cellular respiration (glycolysis, TCA and ETC)Cellular respiration (glycolysis, TCA and ETC)
Cellular respiration (glycolysis, TCA and ETC)
 
Chemistry of Carbohydrates and Nucleic acids - An introduction
Chemistry of Carbohydrates and Nucleic acids - An introductionChemistry of Carbohydrates and Nucleic acids - An introduction
Chemistry of Carbohydrates and Nucleic acids - An introduction
 
ANTIBIOTICS Lecture 06
ANTIBIOTICS Lecture 06ANTIBIOTICS Lecture 06
ANTIBIOTICS Lecture 06
 
ANTIBIOTICS Lecture 05
ANTIBIOTICS Lecture 05ANTIBIOTICS Lecture 05
ANTIBIOTICS Lecture 05
 
Antibiotics Lecture 04
Antibiotics Lecture 04Antibiotics Lecture 04
Antibiotics Lecture 04
 
Antibiotics Lecture 03
Antibiotics Lecture 03Antibiotics Lecture 03
Antibiotics Lecture 03
 
Lecture 02
Lecture 02Lecture 02
Lecture 02
 

Disorders of Purine Metabolism Lecture

  • 1. Disorders of Purine Metabolism Lecturer: Dr. G. K. Maiyoh Department of Medical Biochemistry, School of Medicine, MU March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 1
  • 2. Overview • Introduction • Purine (types) • Purine functions • Sources of purines • Metabolic disorders • Nucleotide degradation • Uric acid and hyperuricemia • In-born errors of Uric acid metabolism • Disorders due to purine catabolism • Disorders due to salvage pathway March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 2
  • 3. WHAT ARE PURINES? • Purines are heterocyclic compound consisting of a pyrimidine ring fused to an imidazole Ring March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 3
  • 4. Purines • Other minor purine base include: 1. Xanthine 2. Hypoxanthine 3. Uric acid • The above occur in free state in the cells 4 N6 –Methyladenine 5 N6 N6 Dimethyladenine 6 N7-Methylguanine • Occur in mamalian RNA March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 4
  • 5. PURINES 7 1,3-Dimethylxanthine(theophylline) found in TEA 8 3,7-Dimethylxanthine(theobromine)found in COCOA 9 1,3,7-Trimethylxanthine(caffiene ) found in coffee This are pharmacologically important March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 5
  • 6. Functions Key functions include; Provision of Energy e.g. ATP, GTP Building blocks for DNA and RNA (along side pyrimidines) Basic conenzymes i.e. NAD and NADH Play role in signal transduction e.g GTP, cAMP, cGMP March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 6
  • 7. Sources of purine ENDOGENOUS • They may be synthesized DE NOVO from small molecules EXOGENOUS • They may be derived from the breakdown of ingested nucleic acid,mostly from cell-rich meat • Plant diets generally poor in purines March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 7
  • 8. Metabolic disorders of purines • They cover a broad spectrum of illnesses with various presentations. Examples of presentations include; • Hyperuricemia • Acute renal failure • Gout • Unexplained neurologic defects (seizures, muscle weakness e.tc) • Developmental disorders • Compulsive self injury and aggression • Immune deficiency • Deafness March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 8
  • 9. Major Categories of Disorders Two major types of disorders occur; i. Those that arise from a Blockage in purine nucleotide degradation pathway ii. Arising from increased activity of nucleotide degradation pathway March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 9
  • 10. Nucleotide degradation • Nucleic acids can survive the acid of the stomach • They are degraded into nucleotides by pancreatic nucleases and intestinal phosphodiesterases in the duodenum. • Components cannot pass through cell membranes, so they are further hydrolyzed to nucleosides. • Nucleosides may be directly absorbed by the intestine or undergo further degradation to free bases and ribose or ribose-1-phosphate by nucleosidases and nucloside phosphorylase. nucleosidase Nucleoside + H2O Nucleoside base + ribose phosphorylase Nucleoside + Pi base + ribose-1-P
  • 11. Catabolism of purines ADA Major pathways of purine catabolism in animals. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 11
  • 12. Catabolism of purines •Purine nucleotide degradation refers to a regulated series of reactions by which purine ribonucleotides and deoxyribonucleotides are degraded to uric acid in humans. •As indicated earlier, two major types of disorders occur in this pathway; • A block of degradation occurs with syndromes involving;- • immune deficiency. •myopathy or •renal calculi. •Increased degradation of nucleotides occurs with syndromes characterized by;- • hyperuricemia and gout, •renal calculi, •anemia or acute hypoxia. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 12
  • 13. Uric Acid (2,6,8-trioxypurine) • This is the end product of purine metabolism in humans • Accumulation of uric acid in blood is reffered to as hyperuricemia • Uric acid is highly insoluble therefore a very slight alteration in the production or solubility will increase levels in blood. • Due to poor solubility, levels in blood are usually near the maximal tolerable limits March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 13
  • 14. Excretion of uric acid • Uric acid is filtered through the glomeruli and most is reabsorbed in the proximal tubules. • More than 80% of uric acid formed in the urine is derived from distal tubular secretion • Urinary excretion is slightly lower in males than females,which may contribute to the higher incidence of hyperuricaemia in men • Renal secretion may be enhanced by uricosonic drugs(e.g probenecid or sulfinpyrazone),which block tubular urate reabsorption
  • 15. Excretion of uric acid • 75% urate leaving the body is in urine • The remaining 25% passes into the intestinal lumen,where it is broken down by intestinal bacteria(URICOLYCIS)
  • 16. HYPERURICAEMIA • This is increase in blood levels of uric acid that is greater than 0.42 mmol/l in men and more than 0.36mmol/l in women • It can occur by two mechanisms: • 1 Increased production(Over Production) • 2 Decreased Excretion (under excretors)
  • 17. Conditions that lead to Increased Uric acid Production – Malignancies – Reyes Syndrome – Downs Syndrome – Sickle cell anemia – Glycogen storage diseases types I,III, IV and V – Hereditary fructose intolerance – Gout – AcylCoA dehydroginase defficiency March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 17
  • 18. Factors contributing to Hyperuraecimia • Increased synthesis of purines(primary Gout) • Secondary GOUT (Other disorder in which there is rapid tissue break down or rapid cellular turnover) • Increase intake of purines • Increase turnover of Nucleic Acids • Increased rate of urate formation • Reduced rate of Excretion
  • 19. Factors contributing to Hyperuraecimia • Sex(plasma uric acid is higher in male than females) • Obesity (Obese people tends to high plasma level of urate) • Diet (subject with high protein diet ,which is also rich in NUCLIEC acids and who do have high alcohol consumption have high levels of plasma urate • Genetic factor(These are very important factor in high plasma urate levels)
  • 20. Other causes may include: • Eclampsia • Lead toxicity • Chronic alcohol ingestion • NOTE Hypouricaemia is not an important chemical disorder in itself
  • 21. Management of disorders Management of disorders of purine nucleotide degradation is dependent upon modifying the specific molecular pathology underlying each disease state. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 21
  • 22. Common treatment for gout: allopurinol Allopurinol is an analogue of hypoxanthine that strongly inhibits xanthine oxidase. Xanthine and hypoxanthine, which are soluble, are accumulated and excreted. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 22
  • 23. In born errors of Uric Acid Metabolism 1. Phosphorybosylpyrophosphate synthase (PRS) superactivity There are two form; i. The severe form which appears in infancy ii. The mild form which presents in adolescence • In both forms, kidney or bladder stone is often the first symptom. • Gout and impairment of kidney function may develop if the condition is not adequately controlled with medication and dietary restrictions. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 23
  • 24. 2. Adenylosuccinase deficiency • Due to lack of the enzyme adenylosuccinate lyase • In general, affected individuals may have a mix of neurological symptoms, which usually includes abnormalities with cognition and movement, autistic features, epilepsy, muscle wasting, and feeding problems. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 24
  • 25. Disorders due to purine catabolism March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 25
  • 26. Myoadenylate Deaminase Deficiency • Also called muscle adenosine monophosphate deaminase deficiency • This is a genetic disease that interferes with the muscle cell's processing of ATP, the key energy molecule of a cell. • The lack of an enzyme that converts ATP to inosine and ammonia may present no symptoms or it may cause exercise-induced cramping. • The disorder is diagnosed through the accumulation of ammonia or inosine monophosphate in muscle tissue • Treatment typically consists of exercise modulation. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 26
  • 27. Xanthine Oxidase Deficiency (XANTHINURIA) • This is a rare hereditary disorder in which there is a deficiency of liver xanthine oxidase • The catabolism of purine stops with xanthine- hypoxanthine stones. • The blood uric acid is very low and there is a high level of urinary excretion of xanthine • There is reduced excretion of urinary uric acid
  • 28. Xanthine Oxidase Deficiency (Xanthinuria) •Xanthine oxidase deficiency, is an inherited metabolic disorder in which there is deficiency of an enzyme needed to process xanthine, a substance found in caffeine and related substances. •If left untreated, xanthinuria can lead to kidney stone formation and subsequent urinary tract diseases. •Additionally, this condition can lead to muscle disorders, due to deposits of xanthine in muscle tissue. •Treatment of the condition involves avoiding foods and drinks that contain xanthine derivatives, such as coffee, tea and colas and maintaining a high fluid 28 March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013
  • 29. Adenosine Deaminase Deficiency • This is a genetic disorder that impairs the immune system and is the basis of severe combined immunodeficiency, or SCID. • Children diagnosed with SCID are typically deficient in almost all immune protection from pathogens and are vulnerable to chronic infections caused by "opportunistic" organisms that ordinarily do not cause disease in healthy people with a normal immune response. • Symptoms of SCID include pneumonia and chronic diarrhea, with impeded growth compared to healthy children. • Additionally, neurological problems such as developmentalGKM/MUSOM/NSPmotor function disorders and March 21, 2013 delay, 210:PATH.2012.2013 29
  • 30. Disorders due to salvage pathway A salvage pathway is a pathway in which nucleotides (Purine and pyrimidine) are synthesized from intermediates in the degradative pathway for nucleotides. There are two critical enzyme defficiencies; I. Hypoxanthine guanige phosphorybosyltransferase (HPRT) defficiency – May be total (Lesch-Nyhan syndrome ) or partal defficiency Partial HPRT-deficient patients present with symptoms similar to total but with a reduced intensity, and in the least severe forms symptoms may be unapparent. I. Adenine phosphorybosyltransferase (APRT) defficiency – The disorder results in accumulation of the insoluble Purine 2,8- dihydroxyadenine. – It can result in nephrolithiasis (kidney stones), acute renal failure March 21, 2013and permanent kidney damage. GKM/MUSOM/NSP 210:PATH.2012.2013 30
  • 31. Lesch-Nyhan Syndrome • Lesch-Nyhan syndrome is a metabolic disorder caused by a deficiency of an enzyme (HPRT) produced by mutations in a gene located on the X chromosome. • The disease is marked by a buildup of uric acid in all body fluids that results in conditions known as hyperuricemia and hyperuricosuria. • Symptoms often include severe gout, impaired muscular control, moderate mental retardation and kidney problems. • These complications frequently emerge in the first year of life. Neurological symptoms can include March 21, 2013 grimacing, GKM/MUSOM/NSP 210:PATH.2012.2013 facial involuntary writhing and repetitive31
  • 32. Gout • Characterised by the accumulation of monosodium urate crystal deposits which result in inflamation in joints and surrounding tissues. • Presentation – Hyperuricemia – Uric acid nephrolithiasis – Acute inflamatory arthritis March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 32
  • 33. Gout • Commonly monoarticular (Affecting the metatarsophalangeal joint of the big toe. • However deposits of sodium urates may aslo occur in; – The elbows – Knees – Feet – Helix of the ear March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 33
  • 34. Figure 28-29 The Gout, a cartoon by James Gilroy (1799). Page 1097 Gout is a disease characterized by elevated levels of uric acid in body fluids. Caused by deposition of nearly insoluble crystals of sodium urate or uric acid. March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 34
  • 35. Types of Gout • Primary Gout – Occurrence: Middle aged men (mostly) – Cause: Overproduction of Uric Acid Decreased renal excretion or both Biochemical Etiology: Not clearly known and is considered a polygenic disease March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 35
  • 36. Types of Gout • Secondary Gout – Occurrence: Children – Cause: other condition in which there is rapid tissue breakdown or cellular turnover – Such condition leads to either; • Increased production of Uric acid • Decreased clearance of Uric acid March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 36
  • 37. Other conditions that could lead to gout • Any other condition that may lead to either; – Decreased uric acid clearance or – Increase in production These may include; Also; • Malignancy therapy •Excessive purine intake •Alcohol intake • Dehydration •Carbohydrate ingestion • Lactic acidosis • Ketoacidosis • Stavation • Diuretic therapy • Renal failure March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 37
  • 38. Hereditary disorders associated with gout • These include 3 key enzymes resulting in hyperuricemia • These are; 1. Severe HPRT defficiency (Lesch-Nyhan syndrome) • Also Partial HPRT defficiency 1. Superactivity of PP-ribose-p synthetase 2. Glucose -6-phosphatase defficiency (glycogen storage disease type 1) March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 38
  • 39. Hereditary disorders associated with gout - cnt • 1st two are caused by hyperuricemia due to purine nucleotide and uric acid overproduction • The 3rd due to excess uric acid production and impaired uric acid secretion March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 39
  • 40. Familial Juvenile Gout (Familial Juvenile Hyperuricemic Nephropathy (FJHN) • Due to severe renal hypoexcretion of uric acid • Presentation usually occurs at puberty to the 3rd decade – Has also been reported in infancy Characteristics – Hyperuricemia – Gout – Familial renal disease – Low urate clearance relative to GFR March 21, 2013 GKM/MUSOM/NSP 210:PATH.2012.2013 40